Saturday, June 1, 2024, Chicago, Illinois, 6:45 AM – 7:45 AM Central Time (7:45 AM – 8:45 AM Eastern Time)

Breakfast with the Investigators: Current and Emerging Role of Antibody-Drug Conjugates in the Treatment of Lung Cancer

A CME Hybrid Symposium Held in Conjunction with the 2024 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400

Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Rebecca S Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Thoracic Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Luis Paz-Ares, MD, PhD
Chair of the Medical Oncology Department
at the Hospital Universitario 12 de Octubre
Associate Professor at the Universidad Complutense
Head of the Lung Cancer Unit at the National Oncology Research Center
Madrid, Spain


Jacob Sands, MD
Physician
Dana-Farber Cancer Institute
Assistant Professor
Harvard Medical School
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, and Daiichi Sankyo Inc.
Program Schedule — Central Time
6:15 AM – 6:45 AM — Registration and Breakfast
6:45 AM – 7:45 AM — Educational Meeting

Discussion Topics

  • MODULE 1: Integration of Antibody-Drug Conjugates (ADCs) into the Care of Patients with Non-Small Cell Lung Cancer (NSCLC) and HER2 Alterations
  • MODULE 2: Emerging Role of TROP2-Targeted ADCs for NSCLC
  • MODULE 3: Other Promising Targets for ADCs in Lung Cancer

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Understand the cellular targets, structural components and mechanisms of action of available and investigational antibody-drug conjugates (ADCs) with documented activity in patients with lung cancer.
  • Evaluate available efficacy and safety findings with HER2-directed ADCs in patients with metastatic non-small cell lung cancer (NSCLC), and assess the optimal placement of this form of therapy in the current treatment algorithm.
  • Consider the biological rationale for the development of ADCs targeting TROP2 for NSCLC, and recognize available efficacy and safety findings with these agents in patients with relapsed/refractory disease.
  • Appreciate the incidence of HER3 overexpression in patients with NSCLC, and develop an understanding of the rationale for and available data with HER3-directed ADCs for metastatic NSCLC with an EGFR mutation.
  • Recognize the spectrum, frequency, severity and optimal management of toxicities associated with novel ADCs with activity in lung cancer, and apply this information to facilitate the safe and effective use of these agents.
  • Recall the design of ongoing clinical trials evaluating novel ADCs or combination strategies with these agents for lung cancer, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Heist — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Biohaven, Claim Therapeutics, Daiichi Sankyo Inc, Lilly, Merck, Novartis, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Agios Pharmaceuticals Inc, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Erasca, Lilly, Mirati Therapeutics Inc, Mythic Therapeutics, Novartis, Turning Point Therapeutics Inc. Dr Paz-Ares — Advisory Committees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, GSK, Janssen Biotech Inc, Lilly, Merck, Mirati Therapeutics Inc, MSD, Novartis, Pfizer Inc, PharmaMar, Roche Laboratories Inc, Sanofi, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Boards of Directors: Altum Sequencing, STAb Therapeutics; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc, MSD, PharmaMar, Sanofi. Dr Sands — Advisory Committee: Curadev; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Medtronic Inc, Pfizer Inc, PharmaMar, Sanofi; Contracted Research: Amgen Inc, Harpoon Therapeutics; Data and Safety Monitoring Board/Committee: Johnson & Johnson Pharmaceuticals.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, and Daiichi Sankyo Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Grand Ballroom (Level 2)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of lung cancer.

There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2024 ASCO Annual Meeting.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.